At what enterprise value was MARLE GROUP acquired in 2016?

During the acquisition of MARLE GROUP by IK PARTNERS in 2016, the transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR.

What was the EV/EBITDA of MARLE GROUP when it was acquired by IK PARTNERS?

The estimated EV/EBITDA multiple for MARLE GROUP is in the range of 10x - 18x.

When was MARLE GROUP acquired by IK PARTNERS?

MARLE GROUP was acquired by IK PARTNERS in 2016.

What was the revenue of MARLE GROUP at the time of the deal?

The revenue of MARLE GROUP at the time of the deal is estimated to be in the range of 50M - 100M EUR.

What was the EBITDA of MARLE GROUP during the acquisition?

MARLE GROUP's EBITDA is estimated to be in the range of 10M - 30M EUR.

How is the data for the MARLE GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MARLE GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/ik-investment-partners-valorise-marle-pres-de-350-m-112563

What is the average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026?

The average EV/EBITDA multiple for the Healthcare & Pharma sector in 2026 is 14.3x.

← DATABASE

Home Database Healthcare & PharmaMARLE GROUP

05/2016

MARLE GROUP acquired by IK PARTNERS

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 300M - 700M EUR

Context

IK Investment Partners has agreed to acquire a majority stake in Marle International from Carlyle Europe Technology. The transaction values the company at approximately EUR350 million. This "Limited Auction" process saw IK prevail over competitors Astorg, Permira, and Ergon. As part of the deal, Carlyle reinvests as a minority shareholder, alongside the founding Marle family and the management team. The acquisition aims to support Marle's continued international expansion and external growth strategy.

It is worth noting that the fund The Carlyle Group took control of Marle Group through an LBO in 2009.

MARLE GROUP, which reported an EBITDA margin of in 2015, is valued in this transaction at an EV/EBITDA multiple of , representing a level the average currently observed in the Healthcare & Pharma sector (14.3x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Marle Group is a world-leading strategic partner and contract development and manufacturing organization (CDMO) dedicated exclusively to the orthopedic and traumatology industry. Headquartered in France, the company provides a complete, vertically integrated value chain—from initial R&D and design assistance to forging, casting, precision machining, specialized coating, and final sterile packaging. Its business model is built on high-precision industrial expertise, supporting global Original Equipment Manufacturers (OEMs) in the production of hip, knee, shoulder, and spine implants, as well as extremity and trauma devices. The organization operates several state-of-the-art production facilities across Europe and the United States, maintaining the most stringent international regulatory certifications (ISO 13485, FDA). Strategically, the firm acts as a mission-critical consolidator in the MedTech supply chain, benefiting from the structural growth in joint replacement surgeries driven by aging global populations and active lifestyles. Its value proposition is centered on "one-stop-shop" efficiency, technical mastery of biocompatible materials, and a commitment to accelerating the time-to-market for innovative surgical solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2015

2014

Other operations with MARLE GROUP

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
12/2023	MARLE GROUP	NOWAK	FRANCE	Implants & Prosthetics
10/2019	DENTRESSANGLE	MARLE GROUP	FRANCE	Implants & Prosthetics
09/2009	THE CARLYLE GROUP	MARLE GROUP	FRANCE	Implants & Prosthetics

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MARLE GROUP by IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: marle group

Acquirer: ik partners